| 注册
首页|期刊导航|中国药房|在美国申请的艾滋病疫苗专利分析

在美国申请的艾滋病疫苗专利分析

秦雪梅 张冬梅

中国药房2016,Vol.27Issue(7):869-871,3.
中国药房2016,Vol.27Issue(7):869-871,3.DOI:10.6039/j.issn.1001-0408.2016.07.02

在美国申请的艾滋病疫苗专利分析

Analysis of AIDS Vaccine Patent Applied in America

秦雪梅 1张冬梅1

作者信息

  • 1. 广东药学院医药商学院,广州 510006
  • 折叠

摘要

Abstract

OBJECTIVE:To provide reference for AIDS vaccine R&D in China through investigating AIDS vaccine patent ap-proval in America. METHODS:By combining keywords as HIV vaccine(s),AIDS vaccine(s) and Vaccine of HIV(AIDS) and classification number as A61K,A61P and C12P,related patents were retrieved from Thomson Innovation platform during Jan. 1981-Mar. 2015,and then analyzed in respects of patent data,patent approval trend,R&D ability,patent technology field distribu-tion,etc. RESULTS:A total of 1 272 patents were retrieved,including 405 valid patents. From 1985 to 2014,there were three stages for the change of AIDS vaccine application quantity,which were slow rise,fast rise and slow decline period;on the whole, the trend was on the rise. The main players were Duke University,United States Department of Health and Human Services,Pas-teur Institute,Connaught Laboratories Limited and Merck Group. AIDS vaccine R&D focused on pharmaceutical preparation,thera-peutic activity of medicinal preparations,microorganism,enzyme,etc. American scientific research institutions focused more on pharmaceutical preparation and peptide study. CONCLUSIONS:Though the AIDS vaccine field develops slowly,the future is still promising. In this field,America has stronger patent advantage and scientific research strength. AIDS vaccine R&D concentrates on pharmaceutical preparation,therapeutic activity of medicinal preparations and composition.

关键词

艾滋病/疫苗/专利/美国

Key words

AIDS/Vaccines/Patent/America

分类

医药卫生

引用本文复制引用

秦雪梅,张冬梅..在美国申请的艾滋病疫苗专利分析[J].中国药房,2016,27(7):869-871,3.

基金项目

广东省省级科技计划项目 ()

中国药房

OA北大核心CSTPCD

1001-0408

访问量0
|
下载量0
段落导航相关论文